Diabetes · 2005 · 212 citations · 45 references
Life SciencesEndocrinologyImmunologyAutoimmunityClinical ImmunologyDiabetologyAutoantibodiesAutoimmune Disease PathogenesisAutoimmune DiseasesAutoimmune EndocrinopathiesAutoimmune InflammationDiabetes MellitusAutoimmune Endocrine DiseaseBiomarkers Of Autoimmune Activity
Latent autoimmune diabetes in adults (LADA) is a disorder in which, despite the presence of islet antibodies at diagnosis of diabetes, the progression of autoimmune beta-cell failure is slow. LADA patients are therefore not insulin requiring, at least during the first 6 months after diagnosis of diabetes. Among patients with phenotypic type 2 diabetes, LADA occurs in 10% of individuals older than 35 years and in 25% below that age. Prospective studies of beta-cell function show that LADA patients with multiple islet antibodies develop beta-cell failure within 5 years, whereas those with only GAD antibodies (GADAs) or only islet cell antibodies (ICAs) mostly develop beta-cell failure after 5 years. Even though it may take up to 12 years until beta-cell failure occurs in some patients, impairments in the beta-cell response to intravenous glucose and glucagon can be detected at diagnosis of diabetes. Consequently, LADA is not a latent disease; therefore, autoimmune diabetes in adults with slowly progressive beta-cell failure might be a more adequate concept. In agreement with proved impaired beta-cell function at diagnosis of diabetes, insulin is the treatment of choice.
45
Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus
Kevan C. Herold, William Hagopian, Julie Auger et al. · New England Journal of Medicine · 2002 · 1.2K citations · Full text
Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
Diabetes Care · 2005 · 671 citations